Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.38 |
| ▸ | MAOB | P27338 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | UNG | P13051 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | NAT1 | P18440 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954279 | 0.78 | MAOA (0.41) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2636655 | 0.78 | MAOA (0.42) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2981955 | 0.76 | ESR1 (0.38) | ALDH1A1 | |
| SCHEMBL3645563 | 0.76 | MAOA (0.46) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL6841543 | 0.72 | ALDH1A1 (0.41) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL25949907 | 0.71 | SLC6A2 (0.52) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL13509648 | 0.70 | MAOA (0.41) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL28004940 | 0.69 | CTSK (0.41) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL1519405 | 0.69 | FDPS (0.41) | RAB9AALDH1A1 | |
| SCHEMBL16334979 | 0.69 | HMGCR (0.43) | MAOAMAOBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| EP-2259681-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009100166-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE1A, PDE4B | MAOA 72/4885MAOB 134/4885NPC1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.